heart-2372134_640

Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

pharmafile | July 30, 2020 | News story | Research and Development Boehringer, Eli Lilly, jardiance, pharma 

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in the treatment of adults with heart failure with reduced ejection fraction, with and without diabetes.

The pair revealed that the 10mg dose of the drug met its primary endpoint in a study of 3,630 participants, successfully reducing the risk of cardiovascular death or hospitalisation as a result of heart failure when used in combination with standard of care.

“Heart failure is a common, but very serious chronic cardiovascular disorder, and it causes substantial disability while threatening the lives of millions of people worldwide,” remarked Dr Milton Packer, Chair of the Executive Committee for the EMPEROR study programme and Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center. “The results of the EMPEROR-Reduced trial indicate that SGLT2 inhibitors have the potential to become a new standard of care for this disease, which will be a meaningful addition to currently established treatments.”

While detailed findings were not released, it was confirmed that full data from the study would be presented at the European Society of Cardiology (ESC) Congress 2020 in late August.

Matt Fellows

Related Content

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …

Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets

Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) …

Isomorphic Labs to collaborate with Eli Lilly

Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli …

Latest content